Ki-67 IHC MIB-1 pharmDx (Dako Omnis)
Agilent Technologies, Inc. · Decision date Sep 11, 2026
What did the FDA decide?
The FDA record for P210026/S003 lists a 30-day notice dated 2026-09-11 under decision code OK30, covering approval of manufacturing process and equipment changes for filling and capping. The stated reason is a process change affecting manufacturer, sterilizer, packager or supplier. The product is Ki-67 IHC MIB-1 pharmDx (Dako Omnis), an immunohistochemistry antibody assay under product code QQT, filed by Agilent Technologies, Inc.
The S003 suffix identifies this as the third supplement to PMA P210026, not a new approval of the assay. A 30-day notice reports a manufacturing change; it does not, by itself, show clinical performance or establish safety or effectiveness. The record does not specify which equipment, line or site changed, what validation accompanied the change, or how filling and capping affect device performance. Those details remain unknown from the supplied fields.
FDA approval order statement
approval of manufacturing process and equipment changes for filling and capping
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210026/S003
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- QQT
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, Ki-67.
- Applicant
- Agilent Technologies, Inc.
- Product code
- QQT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210026 · Original PMA
Ki-67 IHC pharmDx
P210026/S003 received
Application receipt date recorded by FDA.
P210026/S003 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P210026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Ki-67 IHC pharmDxP210026 | Agilent Technologies, Inc. | PMA approval | Oct 12, 2021 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P210026/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records